slides · global inventory
Image
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 119,566
Current window 88,231-88,260
Pages 3,986
Rows per page 30
Component
88,231-88,260 of 119,566
01
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & Context1 hit
02
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & Context1 hit
04
The slide highlights two distinct pipelines: N-GENIUS (cell therapy) and SMARxT (tissue-specific).Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & Context1 hit
06
The table uses a standard pharmaceutical pipeline layout with clinical and preclinical segments.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem & Complication1 hit
07
The slide uses a hub-and-spoke diagram to illustrate the negative consequences of neurotoxicity.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
08
Includes a cartoon liver character, likely representing the target organ or safety profile.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
16
Includes comparative data points for transduction efficiency and experimental data for tonic signaling and anti-exhaustion.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
18
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
30
Includes a process diagram illustrating the mechanism of action of IMX-110 in tumor microenvironments.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
31
Includes survival curves (Kaplan-Meier), tumor imaging, and tumor frequency metrics.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
32
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
37
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
38
The slide uses a process-oriented layout to connect platform capabilities to specific product outputs.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
39
The slide uses a process-like flow from the 3 pillars to the specific product applications.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
40
Includes technical diagrams of the drug construct, comparative histology, and survival curves.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
42
Includes detailed scientific diagrams and references to clinical studies.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
43
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
21
Includes detailed source citations and disclaimer regarding cross-trial comparisons.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
32
Includes a scientific mechanism of action diagram showing iMX-110 effects on tumor microenvironment.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
33
Includes survival curves (Kaplan-Meier), median survival bar chart, and bioluminescence imaging of tumor regression.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
34
Immix Biopharma | Investor Presentation Deck | 52 slidesImmix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
39
Immix Biopharma | Investor Presentation Deck | 52 slidesImmix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
40
The slide uses a process-flow style layout to connect platform capabilities to specific clinical assets.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
41
The slide uses a 3-pillar framework to explain the platform, followed by a product-specific breakdown.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
42
Includes technical diagrams of the drug construct, comparative histology, and survival curves.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
44
The slide uses a two-part structure: clinical efficacy (top right) and mechanism of action (bottom right).Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
45
Immix Biopharma | Investor Presentation Deck | 52 slidesImmix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Team1 hit
50
Immix Biopharma | Investor Presentation Deck | 52 slidesImmix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
51
The slide uses a bar chart to contrast the combined sales of two groups of drugs, illustrating the market size for specific oncology indications.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
52
The slide uses a bar chart comparison to highlight the efficacy gap between established treatments and placebo.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit